Tulobuterol patch - Abbott/Nitto Denko CorporationAlternative Names: Hokunalin
Latest Information Update: 03 Dec 2015
At a glance
- Originator Hokuriku Seiyaku; Nitto Denko
- Developer Abbott Laboratories; Hokuriku Seiyaku; Maruho
- Class Antiasthmatics; Bronchodilators
- Mechanism of Action Beta 2 adrenergic receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Asthma; Bronchitis; Emphysema